Literature DB >> 11368986

Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate.

T E Canto De Cetina1, P Canto, M Ordoñez Luna.   

Abstract

This study purported to determine the effect of pretreatment counseling upon discontinuation of 150 mg depot-medroxyprogesterone acetate (Depo-Provera) given for contraception. A total of 350 Mexican women participated: 175 received detailed structured pretreatment counseling about the hormonal effects of the injectable vs. routine counseling upon duration of use and efficacy of the method. Study termination rates were significantly lower in the structured counseling group than in the control group. Cumulative life table discontinuation rates were 17% (30/175) and 43.4% (76/175), respectively (p <0.05). The most common reasons for terminating DMPA were menstrual changes (8.6 and 32% for counseling and control group, respectively). The findings suggest that pretreatment counseling on expected side effects increases the continuation rates of DMPA users.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368986     DOI: 10.1016/s0010-7824(01)00181-0

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  34 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

Review 2.  Contraceptive counseling: best practices to ensure quality communication and enable effective contraceptive use.

Authors:  Christine Dehlendorf; Colleen Krajewski; Sonya Borrero
Journal:  Clin Obstet Gynecol       Date:  2014-12       Impact factor: 2.190

Review 3.  Choosing non-oral, long-acting reversible contraception.

Authors:  Mary Stewart; Deborah Bateson
Journal:  Aust Prescr       Date:  2016-10-01

4.  Evidence-based guidance on Selected Practice Recommendations for Contraceptive Use: identification of research gaps.

Authors:  Suzanne G Folger; Denise J Jamieson; Emily M Godfrey; Lauren B Zapata; Kathryn M Curtis
Journal:  Contraception       Date:  2012-10-18       Impact factor: 3.375

5.  Identifying counseling needs of nulliparous adolescent intrauterine contraceptive users: a qualitative approach.

Authors:  Margot K Brown; Colette Auerswald; Stephen L Eyre; Julianna Deardorff; Christine Dehlendorf
Journal:  J Adolesc Health       Date:  2012-08-25       Impact factor: 5.012

Review 6.  Eliminating health disparities in unintended pregnancy with long-acting reversible contraception (LARC).

Authors:  Caitlin Parks; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2016-02-12       Impact factor: 8.661

7.  Modified labels for long-term medications: influences on adherence, comprehension and preferences in Malaysia.

Authors:  Huan-Keat Chan; Mohamed Azmi Hassali
Journal:  Int J Clin Pharm       Date:  2014-08-20

8.  Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills.

Authors:  Abbey B Berenson; Susan D Odom; Carmen Radecki Breitkopf; Mahbubur Rahman
Journal:  Am J Obstet Gynecol       Date:  2008-07-03       Impact factor: 8.661

9.  Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.

Authors:  D Heather Watts; Jeong-Gun Park; Susan E Cohn; Song Yu; Jane Hitti; Alice Stek; Pamela A Clax; Laila Muderspach; Juan J L Lertora
Journal:  Contraception       Date:  2007-12-21       Impact factor: 3.375

10.  Women's preferences for contraceptive counseling and decision making.

Authors:  Christine Dehlendorf; Kira Levy; Allison Kelley; Kevin Grumbach; Jody Steinauer
Journal:  Contraception       Date:  2012-11-21       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.